Dali Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dali Li has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Alana L. Welm
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
4 shared publications - Anuj Srivastava
The Jackson Laboratory
4 shared publications - Bryan E. Welm
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
4 shared publications - Dennis A. Dean
Seven Bridges Genomics, Charlestown, USA
4 shared publications - Funda Meric-Bernstam
Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, USA
4 shared publications - Geoffrey I. Shapiro
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
4 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.
- Open Access
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.
- 2 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.
- Open Access
- 19 April 2024
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 23 (7) , 924-938
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
- 19 April 2024
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 23 (7) , 924-938
Open AccessAssessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.